David L. Bushnell, Jr, MD

Professor of Radiology-Division of Nuclear Medicine

Current Positions

Professor of Radiology - Division of Nuclear Medicine

Education

BS in Physics, University of Illinois at Urbana-Champaign, Champaign, Illinois, United States
MD in Medicine, University of Illinois Abraham Lincoln School of Medicine, Chicago, Illinois, United States
Resident in Internal Medicine, Lutheran General Hospital, University of Illinois, affiliate Park Ridge, IL
Resident in Nuclear Medicine, University of Wisconsin Hospital & Clinics
Resident in Nuclear Medicine, University of Wisconsin Hospital & Clinics, Madison, WI
Internship in Internal Medicine, Lutheran General Hospital, Univ. of Illinois, affiliate Park Ridge, IL

Research Interests

Targeted alpha emitter therapy
Targeted Radioisotope therapy using radiolabeled SSTR peptides
Targeted Raionuclide therapy of Prostate cancer
Targeted Radioisotope therapy using I-131 MIBG
Dosimetric approaches to using targeted radionuclide therapies

Licenses & Certifications

Nuclear Medicine, American Board of Nuclear Medicine (ABNM)
Internal Medicine, American Board of Internal Medicine (ABIM)
Iowa Medical License (Permanent), State of Iowa

Selected Publications

Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 Sep 7;115(9):1001-1010. doi: 10.1093/jnci/djad096. PMID: 37255328; PMCID: PMC10483264.
Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clin Nucl Med. 2022 Jun 1;47(6):503-511. doi:10.1097/RLU.0000000000004182. PMID: 35507433.
Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol. 2022 Jun 1;45(6):233-242. doi:10.1097/COC.0000000000000903. Epub 2022 May 4. PMID: 35507413.
Pollard JH, Menda Y, Zamba KD, Madsen M, O'Dorisio MS, O'Dorisio T, Bushnell D. Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. Cancer Biother Radiopharm. 2021 Oct;36(8):632-641. doi: 10.1089/cbr.2020.4633. Epub 2021 Jul 12. PMID: 34252288;PMCID: PMC8817731.
Dillon JS, Bushnell D, Laux DE. High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma. Future Oncol. 2021 Apr;17(10):1131-1141. doi:10.2217/fon-2020-0625. Epub 2021 Jan 28. PMID: 33506713; PMCID: PMC7927907.
Strosberg, J. R., Srirajaskanthan, R., El-Haddad, G., Wolin, E. M., Chasen, B. R., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Hendifar, A. E., Öberg, K., Ruszniewski, P., Santoro, P., Broberg, P., Leeuwenkamp, O. R. & Krenning, E. P. (2021). Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. DOI: 10.2967/jnumed.120.258897. PMID: 33771903.
Bushnell, D. L., Bodeker, K. L., O'Dorisio, T. M., Madsen, M. T., Menda, Y., Graves, S. A., O'Dorisio, M. S. & Zamba GKD (2021). Addition Of ¹³¹I MIBG To PRRT (⁹⁰Y DOTATOC) For Personalized Treatment of Selected Patients with Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. DOI: 10.2967/jnumed.120.254987. PMID: 33517327.
Bushnell, D. L. & Bodeker, K. L. (2020). Overview and Current Status of Peptide Receptor Radionuclide Therapy. Surgical oncology clinics of North America 29 (2) 317-326. DOI: 10.1016/j.soc.2019.11.005. PMID: 32151363.
Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Kunz, P., Hobday, T., Hendifar, A., Oberg, K., Lopera Sierra, M., Thevenet, T., Margalet, I., Ruszniewski, P. & Krenning, E. (2018). Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with¹⁷⁷lu-dotatate in the phase III netter-1 trial. Journal of Clinical Oncology 36 (25) 2578-2584. DOI: 10.1200/JCO.2018.78.5865.
Menda, Y., Madsen, M. T., O'Dorisio, T. M., Sunderland, J., Watkins, L. G., Dillon, J. S., Mott, S. L., Schultz, M. K., Zamba GKD, Bushnell, D. L. & O'Dorisio, M. S. (2018). 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. DOI: 10.2967/jnumed.117.202903. PMID: 29523629.